Sheldon Jay Freedman MD FACS

PubMed

• 12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia.
  Steven A Kaplan, Sijo J Parekattil, Ning Z Wu, Brian Mazzarella, Michael Trotter
  The Journal of Urology. 2026-04-01
• 7 citations
  Preservation of sexual function with Optilume-a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
  Olivia Copelan, Jared Moss, Sheldon Freedman, Karl Coutinho, Dean Elterman
  The Journal of Sexual Medicine. 2025-04-08
• 13 citations
  Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study).
  Steven A Kaplan, Jared L Moss, Sheldon J Freedman
  Prostate Cancer and Prostatic Diseases. 2024-09-01

Journal Articles

• Enzymatic Changes in Experimentally Induced Testicular Torsion.  
  Freedman, S., Chavel, M, Investigative Journal of Urology

Abstracts/Posters

• Impotence, It’s Reversible.
  Freedman, S, Southwest Impotency Center, Van Buren, AR
• A Randomized Double Blind, Placebo Controlled, At-Home Study of Intranasal Apomorphine for the Treatment of Erectile Dysfunction.
  Freedman, S, Sexual Medicine Society of North America

Lectures

• Tolterodine, an Effective and Well Tolerated Treatment for Urge Incontinence and Other Overactive Bladder Symptoms – Clinical Drug Investigation. 
• Questions about Your Urologic Health. 
  Desert Springs Hospital - Senior Advantage Group
• Enablex: A New Competitive Muscarinic Receptor Antagonist. 
  Novartis Pharmaceuticals Corporation